Memantine Hydrochloride Tablet, Coated
Product Images NDC 62332-075

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 62332-075). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine 10 mg

Label for Memantine Hydrochloride Tablets, USP 10 mg by Alembic Pharmaceuticals Inc. The label indicates a package of 30 coated tablets for oral use. It includes dosing information, storage instructions, manufacturer details, a barcode, and a green box highlighting the 10 mg strength. Marked Rx only.*

FDA Label Image

Memantine 5 mg

Memantine Hydrochloride 5 mg coated tablets label from Alembic Pharmaceuticals Inc. The label shows 30 tablets, Rx only, with directions for storage and handling. The barcodes and NDC 62332-075-30 are visible. Manufacturer addresses in Gujarat, India and Bedminster, NJ, USA are included.*

FDA Label Image

Figure 1 (Memantine Fig1)

A line graph showing the change from baseline in ADCS-ADL scores over 28 weeks of treatment comparing placebo and memantine hydrochloride groups. The x-axis represents weeks of treatment, and the y-axis shows mean change with standard error. The memantine group shows less decline compared to placebo.*

FDA Label Image

Figure 2 (Memantine Fig2)

A line graph showing the cumulative percentage of patients completing 28 weeks of double-blind treatment, comparing memantine hydrochloride and placebo. The x-axis represents changes from baseline in ADCS-ADL scores, while the y-axis shows cumulative percentage of patients. The memantine hydrochloride group reaches higher cumulative percentages more rapidly than placebo.*

FDA Label Image

Figure 4 (Memantine Fig4)

A line chart showing cumulative percentage of patients completing 28 weeks of double-blind treatment, comparing placebo and memantine hydrochloride groups based on specified changes from baseline in SIB (Severe Impairment Battery) scores. The x-axis represents change from baseline, and the y-axis shows cumulative percentage of patients.*

FDA Label Image

Figure 6 (Memantine Fig6)

A line graph showing the cumulative percentage of patients completing 24 weeks of double-blind treatment with changes from baseline in ADCS-ADL scores. The x-axis represents ADCS-ADL change from baseline, and the y-axis shows cumulative percentage of patients. Two lines compare Placebo/Donepezil and Memantine hydrochloride/Donepezil treatments.*

FDA Label Image

Figure 7 (Memantine Fig7)

A line graph showing the time course of change from baseline in SIB score over 24 weeks of treatment. One line represents Memantine hydrochloride/Donepezil, showing clinical improvement peaking around week 12 and gradually declining but remaining above baseline. The other line represents Placebo/Donepezil, staying near baseline with a decline after 12 weeks indicating clinical decline. Error bars indicate variability around the means.*

FDA Label Image

Figure 8 (Memantine Fig8)

A cumulative percentage line graph showing patient response over 24 weeks of double-blind treatment, comparing Memantine Hydrochloride/Donepezil versus Placebo/Donepezil. The x-axis represents SIB change from baseline, and the y-axis represents the cumulative percentage of patients. Two lines track patient outcomes differentiated by treatment group.*

FDA Label Image

Figure 3 (Memantine Figure3)

A line graph showing the mean change from baseline in SIB score over 28 weeks of treatment comparing placebo and memantine hydrochloride groups. The y-axis indicates mean change with clinical improvement and decline noted, and the x-axis shows weeks of treatment. The memantine hydrochloride group maintains scores near baseline, while the placebo group declines significantly over time.*

FDA Label Image

Figure 5 (Memantine Figure5)

A line graph showing the time course of change from baseline in ADCS-ADL scores over 24 weeks of treatment comparing memantine hydrochloride/donepezil versus placebo/donepezil. The y-axis indicates mean change from baseline in ADCS-ADL score, with clinical improvement and decline marked by horizontal dashed lines. Data points with error bars are shown at intervals along the x-axis of weeks of treatment.*

FDA Label Image

Memantine Str

Chemical structure of memantine hydrochloride, showing the molecular arrangement including amine (NH2), hydrochloride (HCl), and methyl (CH3) groups within a bicyclic ring system.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.